June 2021 FDA Recall Xylocaine by Fresenius Kabi Usa Llc
D-0651-2021 - Low out of specification results for epinephrine assay.

This Class II drug recall was voluntarily initiated by Fresenius Kabi Usa Llc on June 25, 2021 for the product Xylocaine. The FDA reported the reason for recall as low out of specification results for epinephrine assay.. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0651-2021

Reason for Recall
Low out of specification results for epinephrine assay.
Initiated
06-25-2021
Reported
07-14-2021
Quantity
234,800 vials

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Fresenius Kabi USA LLC
Distributed Nationwide in the USA
Xylocaine-MPF with Epinephrine 1:200,000, (Lidocaine HCl and Epinephrine Injection, USP), 1%, 300 mg/30 mL, (10 mg/mL), 30 mL Single Dose Vial, 25 Vials per Tray, Rx only, Fresenius Kabi USA, LLC, Lake Zurich, IL 60047. Vial NDC 63323-487-07, Tray NDC 63323-487-37

Batch or Lot Expiration Information

Batch# Batch, expiry: Batch 6123435, exp 01/2022; 6124730, 6124731, exp 07/2022